The association between soluble suppression of tumorigenicity-2 and long-term prognosis in patients with coronary artery disease: A meta-analysis

Liu, Niannian; Hang, Tao; Gao, Xiang; Yang, Wenxue; Kong, Wenjie; Lou, Qiaozhen; Yang, Jin‐Ji

doi:10.1371/journal.pone.0238775

Cited by 15 publications

(14 citation statements)

References 51 publications

(68 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…of ST2 (in ACS and CAD patients only) and our current study, meta-multivariate HRs of all-cause mortality in ACS patients are similar, with a respective meta-multivariate HR of 2.48, (95% CI 1.99–2.97) for Liu et al . and HR 2.207, (95% CI 1.160–4.198) in this current study [ 19 ].…”

Section: Discussionmentioning

confidence: 59%

“…Soluble ST2 is an FDA approved biomarker to evaluate prognosis of mortality in chronic heart failure. Previous meta-analyses of sST2 have also been performed in CAD and post-aortic valve replacement patients [ 14 , 16 , 18 , 19 ] and showed that higher sST2 levels were associated with poor clinical outcomes in these populations. The current meta-analysis shows sST2 is associated with risk of poor outcomes of mortality, MACE and adverse cardiovascular events in a wide definition of CVD patients as well as community populations without identified cardiovascular disease.…”

Section: Discussionmentioning

confidence: 99%

“…Soluble ST2 has been evaluated in a number of clinical CVD studies and is a Food and Drug Administration (FDA) approved prognostic biomarker of mortality in chronic heart failure patients [ 13 ]. Previous meta-analyses have shown that sST2 has diagnostic value for heart failure and is prognostic for all-cause mortality in heart failure, coronary artery disease and following aortic valve replacement [ 14 – 19 ]. However, there is a paucity of clinical studies on IL-33, which is likely due to difficultly measuring circulating levels [ 20 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Role of the IL-33/ST2 axis in cardiovascular disease: A systematic review and meta-analysis

et al. 2021

View full text Add to dashboard Cite

Interleukin (IL)-33 and its unique receptor, ST2, play a pivotal role in the immune response to infection and stress. However, there have been conflicting reports of the role of IL-33 in cardiovascular disease (CVD) and the potential of this axis in differentiating CVD patients and controls and with CVD disease severity, remains unclear. Aims 1) To quantify differences in circulating IL-33 and/or sST2 levels between CVD patients versus controls. 2) Determine association of these biomarkers with mortality in CVD and community cohorts. Methods and results Using Pubmed/MEDLINE, Web of Science, Prospero and Cochrane databases, systematic review of studies published on IL-33 and/or sST2 levels in patients with CVD (heart failure, acute coronary syndrome, atrial fibrillation, stroke, coronary artery disease and hypertension) vs controls, and in cohorts of each CVD subtype was performed. Pooled standardised mean difference (SMD) of biomarker levels between CVD-cases versus controls and hazard ratios (HRs) for risk of mortality during follow-up in CVD patients, were assessed by random effects meta-analyses. Heterogeneity was evaluated with random-effects meta-regressions. From 1071 studies screened, 77 were meta-analysed. IL-33 levels were lower in HF and CAD patients vs controls, however levels were higher in stroke patients compared controls [Meta-SMD 1.455, 95% CI 0.372–2.537; p = 0.008, I2 = 97.645]. Soluble ST2 had a stronger association with risk of all-cause mortality in ACS (Meta-multivariate HR 2.207, 95% CI 1.160–4.198; p = 0.016, I2 = 95.661) than risk of all-cause mortality in HF (Meta-multivariate HR 1.425, 95% CI 1.268–1.601; p<0.0001, I2 = 92.276). There were insufficient data to examine the association of IL-33 with clinical outcomes in CVD. Conclusions IL-33 and sST2 levels differ between CVD patients and controls. Higher levels of sST2 are associated with increased mortality in individuals with CVD. Further study of IL-33/ST2 in cardiovascular studies is essential to progress diagnostic and therapeutic advances related to IL-33/ST2 signalling.

show abstract

Section: Discussionmentioning

confidence: 59%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Role of the IL-33/ST2 axis in cardiovascular disease: A systematic review and meta-analysis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…With regard to general patient characteristics, no significant differences were observed in our patient cohort with the exception of previously known CAD. Outcome analyses for sST2 in CAD have been performed in the past and higher baseline concentrations were associated with a risk of major adverse cardiac events in a recent meta-analysis of 17,432 individuals 24 . Nevertheless, this finding must be interpreted with caution, since some patients in our cohort were certainly overestimated based on their medical records (CAD present, but clinically insignificant) whereas other patients were underdiagnosed, because not all patients received coronary angiography after CPR.…”

Section: Discussionmentioning

confidence: 99%

Soluble suppression of tumorigenicity 2 as outcome predictor after cardiopulmonary resuscitation: an observational prospective study

Rezar

Paar

Seelmaier

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Prognostication after cardiopulmonary resuscitation (CPR) is complex. Novel biomarkers like soluble suppression of tumorigenicity 2 (sST2) may provide an objective approach. A total of 106 post-CPR patients were included in this single-center observational prospective study. Serum sST2 levels were obtained 24 h after admission. Individuals were assigned to two groups: patients below and above the overall cohort’s median sST2 concentration. Primary outcome was a combined endpoint at 6 months (death or Cerebral Performance Category > 2); secondary endpoint 30-day mortality. A uni- and multivariate logistic regression analysis were conducted. Elevated sST2-levels were associated with an increased risk for the primary outcome (OR 1.011, 95% CI 1.004–1.019, p = 0.004), yet no patients with poor neurological outcome were observed at 6 months. The optimal empirical cut-off for sST2 was 46.15 ng/ml (sensitivity 81%, specificity 53%, AUC 0.69). Levels above the median (> 53.42 ng/ml) were associated with higher odds for both endpoints (death or CPC > 2 after 6 months: 21% vs. 49%, OR 3.59, 95% CI 1.53–8.45, p = 0.003; death after 30 days: 17% vs. 43.3%, OR 3.75, 95% CI 1.52–9.21, p = 0.003). A positive correlation of serum sST2 after CPR with mortality at 30 days and 6 months after cardiac arrest could be demonstrated.

show abstract

“…The functional ligand for the ST2L receptor is Interleukin-33 (IL-33). Local tissue inflammation and necrotic cell death as a danger signal trigger the IL-33 secretion ( 26 ). Expressed by cardiomyocytes and cardiac fibroblasts, an excess of sST-2 leads to binding and subsequent reduced bioavailability of circulating cardioprotective ligand IL-33, which reduces apoptosis and improves myocardial function.…”

Section: Introductionmentioning

confidence: 99%

Analysis of Selected Cardiovascular Biomarkers in Takotsubo Cardiomyopathy and the Most Frequent Cardiomyopathies

Topf

Mirna

Bacher

et al. 2021

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Introduction: Among the causes of de novo diagnosed cardiomyopathy, Takotsubo cardiomyopathy (TTC) plays a minor role, with an occurrence of 50,000–100,000 cases per annum in the United States. In clinical practice, a differentiation of a TTC toward an ischemic cardiomyopathy (ICMP) or a dilatative cardiomyopathy (DCMP) appears to be challenging, especially in a subacute setting or in atypical types of TTC.Methods: To investigate this issue, we analyzed serum levels of sST2, GDF-15, suPAR, HFABP, and clinical parameters including echocardiography in 51 patients with TTC, 52 patients with ischemic cardiomyopathy (ICMP) and 65 patients with dilated cardiomyopathy (DCMP).Results: sST-2 seemed to be the most promising biomarker for prediction of a TTC in differential diagnosis to an ICMP (AUC: 0.879, p = < 0.001, Cut off values: 12,140.5 pg/ml) or to a DCMP (AUC: 0.881, p = < 0.001, cut off value: 14521.9 pg/ml). GDF-15 evidenced a slightly lower AUC for prediction of a TTC in differential diagnosis to an ICMP (AUC: 0.626, p = 0.028) and to a DCMP (AUC: 0.653, p = 0.007). A differential diagnostic value was found for H-FABP in the prediction of a DCMP compared to TTC patients (AUC: 0.686, p = < 0.001). In propensity score matching for left ventricular ejection fraction, sex, and cardiovascular risk factors, differences in the plasma levels of sST2 and H-FABP in the matched cohort of TTC vs. DCMP remained statistically significant. In the matched cohort of TTC vs. ICMP, differences in sST2 also remained statistically significantConclusion: As medical therapy, long term prognosis, interval of follow-ups, rehabilitation program and recommendations differ completely between TTC and ICMP/DCMP, biomarkers for differential diagnosis, or rather for confirmation of diagnosis, are warranted in cases of cardiomyopathies with unsure origin. sST-2, GDF-15 and H-FABP might facilitate the classification.

show abstract

The association between soluble suppression of tumorigenicity-2 and long-term prognosis in patients with coronary artery disease: A meta-analysis

Cited by 15 publications

References 51 publications

Role of the IL-33/ST2 axis in cardiovascular disease: A systematic review and meta-analysis

Role of the IL-33/ST2 axis in cardiovascular disease: A systematic review and meta-analysis

Soluble suppression of tumorigenicity 2 as outcome predictor after cardiopulmonary resuscitation: an observational prospective study

Analysis of Selected Cardiovascular Biomarkers in Takotsubo Cardiomyopathy and the Most Frequent Cardiomyopathies

Contact Info

Product

Resources

About